

N Please replace lines 7-9 on page 93 with
SEQ ID NO:1 is the amino acid sequence for HSPDE1B2. For comparative purposes the
sequence for HSPDE1B1 (SEQ ID NO:3) is shown in as a comparison using CLUSTAL W
(1.74) multiple sequence alignment

N Please replace lines 3-5 on page 94 with
SEQ ID NO:2 is the nucleotide sequence for HSPDE1B2. For comparative purposes the
sequence for HSPDE1B1 (SEQ ID NO:4) is shown in as a comparison using CLUSTAL W
(1.74) multiple sequence alignment

In the Claims:

Please amend claims 11, 12, and 16 as follows:

11. (Amended) A method of affecting in vivo PDE1B2 activity or expression
with an agent;
wherein the agent is capable of affecting PDE1B2 activity or expression in an in
vitro assay method;
wherein the in vitro assay method is the assay method defined in claim 8 or claim 9,
said method comprising administering said agent to a subject.

B11
12. (Amended) Use of an agent in the preparation of a A pharmaceutical
composition for the treatment of a disease or condition associated with PDE1B2, the agent
is said composition comprising an agent capable of having an effect on the activity or
expression of PDE when assayed in vitro by the assay method according to claim 8 or
claim 9.

B12
16. (Amended) Use of an agent which has an effect on the activity of PDE1B2
or the expression thereof in the preparation of a A pharmaceutical composition for the
treatment of a disease or condition associated with PDE1B2, said composition comprising
an agent which has an effect on the activity of PDE1B2 or the expression thereof.